Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Jennifer E. Amengual, Hongli Li, Patrick M. Reagan, Tareq Al Baghdadi, Hayder Saeed, Joseph M Unger, Alexey Danilov, Michael Leblanc, Jonathan W. Friedberg, Sonali M. Smith

Blood (2024) 144 (Supplement 1): 3123.2.

https://doi.org/10.1182/blood-2024-199784

Published: 2024

Journal Articles

Disparities in Clinical Trial Participation Among Medicare Beneficiaries with Hematologic Malignancies from 2006 to 2019: A SEER-Medicare Analysis

Inna Y Gong, Meredith Rosenthal, Mark Soto, Bahar Rafinejad-Farahani, Joseph M Unger, Carmen E Guerra, Rena M Conti, Danielle Rodin

Blood (2024) 144 (Supplement 1): 5113.

https://doi.org/10.1182/blood-2024-206089

Published: 2024

Journal Articles

Disparities in Phase II and III Clinical Trial Enrollment for Hematologic Malignancies

Inna Y Gong, Bahar Rafinejad-Farahani, Haris Majeed, Mark Soto, Rena M Conti, Joseph M Unger, Carmen E Guerra, Meredith Rosenthal, Danielle Rodin

Blood (2024) 144 (Supplement 1): 5100.

https://doi.org/10.1182/blood-2024-206450

Published: 2024

Journal Articles

Representation of Minorities in Therapeutic Clinical Trials - a 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)

Alvaro J Alencar, Susan M. Geyer, Electra D Paskett, Levi D. Pederson, Travis Dockter, Nilanjan Ghosh, Kehinde Adekola, Joseph M Unger, Opeyemi Jegede, Jonathan W. Friedberg, Brad S. Kahl, Shira N. Dinner, Nancy L. Bartlett, Kristie A. Blum, John P. Leonard

Blood (2024) 144 (Supplement 1): 110.

https://doi.org/10.1182/blood-2024-209365

Published: 2024

Journal Articles

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

Daniel O. Persky, Thomas P. Miller, Joseph M. Unger, Catherine M. Spier, Soham Puvvada, B. Dino Stea, Oliver W. Press, Louis S. Constine, Kevin P. Barton, Jonathan W. Friedberg, Michael LeBlanc, Richard I. Fisher

Blood (2015) 125 (2): 236–241.

https://doi.org/10.1182/blood-2014-06-584623

Published: 2015

Journal Articles

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

Daniel O Persky, MD, Thomas P. Miller, MD, Joseph M Unger, PhD, Catherine M. Spier, MD, Soham D. Puvvada, MD, B. Dino Stea, MDPhD, Oliver W. Press, MD PhD, Louis Constine, MD, Kevin Barton, MD, Michael LeBlanc, PhD, Sonali Smith, MD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD

Blood (2014) 124 (21): 4414.

https://doi.org/10.1182/blood.V124.21.4414.4414

Published: 2014

Journal Articles

A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515

Alison T. Stopeck, Joseph M. Unger, Lisa M. Rimsza, Michael LeBlanc, Brent Farnsworth, Maria Iannone, Martha J. Glenn, Richard I. Fisher, Thomas P. Miller

Blood (2012) 120 (6): 1210–1217.

https://doi.org/10.1182/blood-2012-04-423079

Published: 2012

Journal Articles

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

Oliver W. Press, MD, PhD, Joseph M Unger, Ph.D., Lisa M. Rimsza, MD, Jonathan Friedberg, MD, Michael LeBlanc, Ph.D., Myron S. Czuczman, MD, Mark S. Kaminski, MD, Rita M. Braziel, MD, David G. Maloney, MD, PhD, Bruce D. Cheson, MD, Thomas P. Miller, MD, Richard I Fisher, MD

Blood (2011) 118 (21): 98.

https://doi.org/10.1182/blood.V118.21.98.98

Published: 2011

Journal Articles

R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433

Jonathan W. Friedberg, MD, Joseph M Unger, Ph.D., W. Richard Burack, Ajay K Gopal, MD, Michael LeBlanc, Ph.D., Oliver W. Press, MD, PhD, Thomas P. Miller, MD, Richard I Fisher, MD

Blood (2010) 116 (21): 590.

https://doi.org/10.1182/blood.V116.21.590.590

Published: 2010

Journal Articles

Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515

Alison T. Stopeck, MD, Joseph M Unger, Ph.D., Lisa M. Rimsza, MD, Brent Farnsworth, DO, Michael LeBlanc, Ph.D., Maria Iannone, MS, Richard I Fisher, MD, Thomas P. Miller, MD

Blood (2010) 116 (21): 591.

https://doi.org/10.1182/blood.V116.21.591.591

Published: 2010

Journal Articles

Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313)

Thomas P. Miller, MD, Joseph M Unger, MS, Catherine Spier, MD, Baldassarre Stea, MD, PhD, Oliver W. Press, MD, PhD, Jonathan W. Friedberg, MD, Michael LeBlanc, PhD, Richard I Fisher, MD

Blood (2008) 112 (11): 3598.

https://doi.org/10.1182/blood.V112.11.3598.3598

Published: 2008

Journal Articles

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP

Lisa M. Rimsza, Michael L. LeBlanc, Joseph M. Unger, Thomas P. Miller, Thomas M. Grogan, Daniel O. Persky, Ralph R. Martel, Constantine M. Sabalos, Bruce Seligmann, Rita M. Braziel, Elias Campo, Andreas Rosenwald, Joseph M. Connors, Laurie H. Sehn, Nathalie Johnson, Randy D. Gascoyne

Blood (2008) 112 (8): 3425–3433.

https://doi.org/10.1182/blood-2008-02-137372

Published: 2008

Includes: Supplemental data

Journal Articles

Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438)

John A. Thompson, Richard I. Fisher, Michael LeBlanc, Stephen J. Forman, Oliver W. Press, Joseph M. Unger, Auayporn P. Nademanee, Patrick J. Stiff, Stephen H. Petersdorf, Alexander Fefer

Blood (2008) 111 (8): 4048–4054.

https://doi.org/10.1182/blood-2007-09-111708

Published: 2008

Journal Articles

Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues.

Lisa M. Rimsza, MD, Michael L. LeBlanc, PhD, Robin A. Roberts, BS, Joseph M. Unger, MS, Thomas P. Miller, MD, Constantine M. Sabalos, MS, Ralph R. Martel, PhD, Elias Campo, MD, Andreas Rosenwald, MD, Joseph M. Connors, MD, Laurie H. Sehn, MD, Natalie Johnson, MD, Randy D. Gascoyne, MD

Blood (2007) 110 (11): 50.

https://doi.org/10.1182/blood.V110.11.50.50

Published: 2007

Journal Articles

Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy with Interleukin-2 Versus Observation for Patients with Non-Hodgkin’s Lymphoma: Results of a Phase III Randomized Trial by the Southwest Oncology Group (SWOG 9438).

John A. Thompson, MD, Richard I. Fisher, MD, Michael L. LeBlanc, PhD, Joseph M. Unger, MS, Stephen J. Forman, MD, Patrick J. Stiff, MD, Alexander Fefer, MD

Blood (2006) 108 (11): 326.

https://doi.org/10.1182/blood.V108.11.326.326

Published: 2006

Journal Articles

Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions

Blood (2006) 107 (3): 1101–1107.

https://doi.org/10.1182/blood-2005-04-1510

Published: 2006

Journal Articles

Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014).

Thomas P. Miller, MD, Joseph M. Unger, MS, Catherine Spier, MD, Baldassarre Stea, MD, PhD, Emilia Cantu, BA, Michael LeBlanc, PhD, Richard I. Fisher, MD

Blood (2004) 104 (11): 158.

https://doi.org/10.1182/blood.V104.11.158.158

Published: 2004

Journal Articles

Fc γ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800).

David G. Maloney, MD, PhD, Barbara Pender-Smith, MS, Joseph M. Unger, MS, Rita M. Braziel, MD, Jerald Radich, MD, Oliver W. Press, MD, PhD, Thomas P. Miller, MD, Thomas M. Grogan, MD, Michael LeBlanc, PhD, Richard I. Fisher, MD

Blood (2004) 104 (11): 589.

https://doi.org/10.1182/blood.V104.11.589.589

Published: 2004

Journal Articles

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project

Lisa M. Rimsza, Robin A. Roberts, Thomas P. Miller, Joseph M. Unger, Michael LeBlanc, Rita M. Braziel, Dennis D. Weisenberger, Wing C. Chan, H. Konrad Muller-Hermelink, Elaine S. Jaffe, Randy D. Gascoyne, Elias Campo, Deborah A. Fuchs, Catherine M. Spier, Richard I. Fisher, Jan Delabie, Andreas Rosenwald, Louis M. Staudt, Thomas M. Grogan

Blood (2004) 103 (11): 4251–4258.

https://doi.org/10.1182/blood-2003-07-2365

Published: 2004

Journal Articles

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

Oliver W. Press, Joseph M. Unger, Rita M. Braziel, David G. Maloney, Thomas P. Miller, Michael LeBlanc, Ellen R. Gaynor, Saul E. Rivkin, Richard I. Fisher

Blood (2003) 102 (5): 1606–1612.

https://doi.org/10.1182/blood-2003-01-0287

Published: 2003

NARROW

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Disparities in Clinical Trial Participation Among Medicare Beneficiaries with Hematologic Malignancies from 2006 to 2019: A SEER-Medicare Analysis

Disparities in Phase II and III Clinical Trial Enrollment for Hematologic Malignancies

Representation of Minorities in Therapeutic Clinical Trials - a 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433

Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515

Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313)

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP

Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues.

Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions

Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014).

Fc γ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800).

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only